RT Journal Article
SR Electronic
T1 Molecular epidemiology of SARS-CoV-2 in Greece reveals low rates of onward virus transmission after lifting of travel restrictions based on risk assessment during summer 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.31.21250868
DO 10.1101/2021.01.31.21250868
A1 Kostaki, Evangelia Georgia
A1 Pavlopoulos, Georgios A.
A1 Verrou, Kleio-Maria
A1 Ampatziadis-Michailidis, Giannis
A1 Harokopos, Vaggelis
A1 Hatzis, Pantelis
A1 Moulos, Panagiotis
A1 Siafakas, Nikolaos
A1 Pournaras, Spyridon
A1 Hadjichristodoulou, Christos
A1 Chatzopoulou, Fani
A1 Chatzidimitriou, Dimitrios
A1 Panagopoulos, Periklis
A1 Lourida, Panagiota
A1 Argyraki, Aikaterini
A1 Lytras, Theodoros
A1 Sapounas, Spyros
A1 Gerolymatos, Gerasimos
A1 Panagiotakopoulos, Georgios
A1 Prezerakos, Panagiotis
A1 Tsiodras, Sotirios
A1 Sypsa, Vana
A1 Hatzakis, Angelos
A1 Anastassopoulou, Cleo
A1 Spanakis, Nikolaos
A1 Tsakris, Athanasios
A1 Dimopoulos, Meletios Athanasios
A1 Kotanidou, Anastasia
A1 Sfikakis, Petros
A1 Kollias, Georgios
A1 Magiorkinis, Gkikas
A1 Paraskevis, Dimitrios
YR 2021
UL http://medrxiv.org/content/early/2021/02/02/2021.01.31.21250868.abstract
AB Molecular epidemiology has provided an additive value to traditional public health tools by identifying SARS-CoV-2 clusters, or providing evidence that clusters based on virus sequences and contact tracing are highly concordant. Our aim was to infer the levels of virus importation and to estimate the impact of public health measures related to travel restrictions to local transmission in Greece. Our phylogenetic and phylogeographic analyses included 389 SARS-CoV-2 sequences collected during the first 7 months of the pandemic in Greece and a random collection in 5 replicates of 3,000 sequences sampled globally, as well as the best hits to our dataset identified by BLAST. Phylogenetic analyses revealed the presence of 70 genetically distinct viruses identified as independent introductions into Greece. The proportion of imported strains was 41%, 11.5%, and 8.8% during the three periods of sampling, namely, March (no travel restrictions), April to June (strict travel restrictions), and July to September (lifting of travel restrictions based on a thorough risk assessment), respectively. These findings reveal low levels of onward transmission from imported cases during summer and underscore the importance of targeted public health measures that can increase the safety of international travel during a pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge support of the next generation sequencing and bioinformatic analysis by the project 'The Greek Research Infrastructure for Personalised Medicine (pMED-GR)' (MIS 5002802) which is implemented under the Action 'Reinforcement of the Research and Innovation Infrastructure', funded by the Operational Programme 'Competitiveness, Entrepreneurship and Innovation' (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund) and the Uni-Pharma S.A. We also acknowledge support of National Public Health Organization, the Greek Shipowners' Social Welfare Company SYN-ENOSIS and the Public Benefit Foundation 'John S. Latsis'.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics and Bioethics Committee of the Medical School, of the National and Kapodistrian University of Athens (protocol #300/25-05-2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be made available in public databases.